CuraGen is abandoning its velafermin program after the therapy flunked a mid-stage trial for preventing mouth ulcerations in cancer patients. CuraGen enrolled 390 patients to see if the therapy could reduce the incidence of severe oral mucositis, the primary endpoint in the failed study. With velafermin on the shelf, CuraGen says it will now shift its focus to belinostat, a mid-stage cancer therapy being studied as a therapy targeting solid tumors and malignancies.
"We continue to aggressively focus on our goal of advancing the belinostat and CR011-vcMMAE programs toward initiation of Phase III development in 2008, and we look forward to presenting updated clinical trial results on these programs in October at the AACR-NCI-EORTC conference, and in December at the ASH annual meeting," said CEO Timothy Shannon.
- check out the release for more info
Roche snares CuraGen's 454 Life Sciences. Report
Read more on: CuraGen